Companies Investors People

Loading

aVenture is in Beta: research coverage is expanding as we build, so please independently verify key details before making investment decisions.

aVenture is in Beta: research coverage is expanding as we build, so please independently verify key details before making investment decisions.

Get in Touch

Contact
Request a Demo
Request Data Updates
Add a Company

Research

Companies
Investors
People

aVenture

Download App
Pricing

Resources

Documentation
Use Cases
CLI
MCP
Feature Requests
Sitemap

Member

Backed by

Ask AI about aVenture

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy · Terms of Service

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading

Jeff Aronin - aVenture Research

Jeff Aronin

AddedMar 31, 2024

UpdatedOct 13, 2026

Jeff Aronin

Jeff Aronin

Founder & CEO, Paragon Biosciences

Jeff Aronin's Career

Harmony Biosciences

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview

aVenture product preview

aVenture product preview

Public$1.2BPlymouth Meeting, PA, US

Board Member· Board

Co-Founder

Discover Financial Services

$35.3BRiverwoods, IL, US

Board Member· Board

Matter

Non-ProfitChicago, IL, US

Board Member· Board

Evozyne

Series B$144.4MChicago, IL, US

Board Member· Board

Paragon Biosciences

Late Stage Private$564.6MChicago, IL, US

Board Member· Board

Founder & CEO· C-Suite · Management

Founder

Castle Creek Biosciences

Late Stage Private$309.4MExton, PA, US

Board Member· Board

Co-Founder

Emalex Biosciences

Series D$1BChicago, IL, US

Founder

People Similar to Jeff Aronin

Mara AspinallBoard Member · GenePeeks

G. Bradley ColeBoard Member · Kiniksa Pharmaceuticals

Burt AdelmanBoard Member · Verve Therapeutics

Joel DudleyBoard Member · Harmonic Discovery

David T. ScaddenCo-Founder · Clear Creek Bio

Leadership at Harmony Biosciences

Jack NielsenBoard Member

Jeffrey M. DaynoCEO

Bob RepellaCo-Founder

Linda SzyperBoard Member

Jeff DaynoBoard Member

Similar to Harmony Biosciences

Ovid TherapeuticsNew York City, NY, USTherapeuticsest. 2014Ovid TherapeuticsNew York City, NY, US · est. 2014

NY-based Ovid Therapeutics Inc. develops medicines for rare neurological disorders.

Public · $184.1M40

Recent news

Discover it Cash Back reviewFintiex · 2026

Discover Card News: What is Changing with Capital One Acquisition in 2026Gerald · 2026

Discover it Cash Back Review: Are Rotating Rewards Worth It?MarketReview · 2026

Leadership at Discover Financial Services

John GreeneEVP, Chief Financial Officer

J. Michael ShepherdInterim CEO and President

Mary BushBoard Member

Gregory CaseBoard Member

Frank GrossmanBoard Member

Similar to Discover Financial Services

HappenSan Francisco, CA, USest. 2006HappenSan Francisco, CA, US · est. 2006

Happen is a San Francisco digital bank offering consumer lending, deposit accounts, and credit-management tools online and by mobile.

Public · $392.2M1.6k

Leadership at Matter

Marco De PoloBoard Member

Andrew CittadineBoard Member

Karen TeitelbaumBoard Member

Steven GouldBoard Member

Meg BarronBoard Member

Holly CopelandBoard Member

Leadership at Evozyne

Rama RanganathanFounder

Similar to Evozyne

Cyrus BiotechnologySeattle, WA, USBiologics, Therapeuticsest. 2014Cyrus BiotechnologySeattle, WA, US · est. 2014

Cyrus Biotechnology is a Seattle-based computational protein design company that engineers biologics from natural proteins for therapeutic indications.

Series B · $32M36

EvolutionaryScaleNew York, NY, USest. 2023EvolutionaryScaleNew York, NY, US · est. 2023

Developer of frontier AI models for the life sciences, including protein models used to understand and design proteins.

Evozym BiologicsLewes, DE, USEnzymes, Proteinsest. 2009Evozym BiologicsLewes, DE, US · est. 2009

Evozym Biologics, Inc. leverages biotech and computation to develop novel proteins for industrial applications and genomics products.

Adaptyv BiosystemsLausanne, canton Vaud, CHProtein Engineeringest. 2020Adaptyv BiosystemsLausanne, canton Vaud, CH · est. 2020

Adaptyv Biosystems: Innovating protein engineering with advanced technology.

Pre-Seed · $3.1M7

Similar to Paragon Biosciences

Paratus SciencesNew York City, NY, USHealth Solutions, Therapeuticsest. 2021Paratus SciencesNew York City, NY, US · est. 2021

Paratus Sciences: A biotech start-up leveraging bat biology for innovative human health solutions.

Series A · $100M38

Palladium Life SciencesChicago, IL, USPharmaceuticalsest. 2013Palladium Life SciencesChicago, IL, US · est. 2013

Palladium Life Sciences, LLC: Chicago-based pharmaceutical company since 2013.

Series A · $4M5

Arbor BiotechnologiesCambridge, MA, USGene Editingest. 2016Arbor BiotechnologiesCambridge, MA, US · est. 2016

Arbor Biotechnologies: Pioneering biodiscovery with AI, genome sequencing, and high-throughput screening.

Series B · $230.6M170

Regenerative BioCambridge, MA, USPharmaceuticalsest. 2020Regenerative BioCambridge, MA, US · est. 2020

Regenerative Bio: AI-driven biotech firm pioneering anti-aging solutions through pharmaceutical tech.

Angel · $10M13

Leadership at Castle Creek Biosciences

Michael DerbyCo-Founder

Matthew GantzBoard Member

Similar to Castle Creek Biosciences

Krystal BiotechPittsburgh, PA, USGene Therapyest. 2017Krystal BiotechPittsburgh, PA, US · est. 2017

Krystal Biotech: A Pennsylvania-based biopharmaceutical firm pioneering gene therapy for rare disorders.

Public · $546M210

Palvella TherapeuticsWayne, PA, USDrugs, Therapeuticsest. 2015Palvella TherapeuticsWayne, PA, US · est. 2015

Palvella Therapeutics: A Pennsylvania-based biopharmaceutical company specializing in rare genetic diseases.

Series D · $106.8M59

Kate TherapeuticsSan Diego, CA, USGene TherapyKate TherapeuticsSan Diego, CA, US

KateTx, a gene therapy biotech firm, focuses on developing AAV-based therapies for genetic muscle and heart diseases.

Series A · $51M44

Basecamp BioWaltham, MA, USGene Therapies, Immunotherapiesest. 2021Basecamp BioWaltham, MA, US · est. 2021

Basecamp Bio: Pioneering cell, gene therapies, regenerative medicine, and immunotherapies research.

Angel · $14M441

Leadership at Emalex Biosciences

Eric MessnerCEO

Similar to Emalex Biosciences

Eumentis TherapeuticsBoston, MA, USDrugsest. 2019Eumentis TherapeuticsBoston, MA, US · est. 2019

Eumentis: A biopharmaceutical firm innovating novel drugs for neurodevelopmental and neurodegenerative disorders.

Series A · $8.9M5

Paragon BiosciencesChicago, IL, USBiopharmaceuticalsest. 2010Paragon BiosciencesChicago, IL, US · est. 2010

Chicago-based Paragon innovates in life sciences, focusing on AI, gene therapy, synthetic biology, and biopharmaceuticals.

Late Stage Private · $564.6M26

Emergo TherapeuticsDurham, NC, USPharmaceuticalsest. 2017Emergo TherapeuticsDurham, NC, US · est. 2017

Emergo Therapeutics: A pharma startup innovating flu treatments for balanced immunity.

Series A · $16M31

Euthymics BioscienceCambridge, MA, USPharmaceuticalsest. 2009Euthymics BioscienceCambridge, MA, US · est. 2009

Euthymics Bioscience: A neuroscience-focused company developing advanced treatments for depression and CNS disorders.

Series A · $38.5M30

Astria TherapeuticsBoston, MA, USBiopharmaceuticalsest. 2008

Astria TherapeuticsBoston, MA, US · est. 2008

Astria Therapeutics, Inc.: A clinical-stage biopharmaceutical company developing treatments for rare diseases and lipid disorders.

Public · $656.4M24

SpringWorks TherapeuticsStamford, CT, USPharmaceuticalsest. 2017SpringWorks TherapeuticsStamford, CT, US · est. 2017

SpringWorks Therapeutics develops pharmaceutical drugs for oncology, neurology, and rare genetic diseases in the US.

Public · $1B227

NeuroviaSan Francisco, CA, USDrugs, Therapeuticsest. 2013NeuroviaSan Francisco, CA, US · est. 2013

NeuroVia, Inc.: A US-based biopharmaceutical company developing therapies for neurological diseases.

Public · $14M75

Best EggWilmington, DE, US

est. 2014

Best EggWilmington, DE, US · est. 2014

Best Egg is a Wilmington, Delaware-based consumer financial technology platform offering personal loans, credit cards, and financial health tools.

$225M

Prosper MarketplaceSan Francisco, CA, USest. 2005Prosper MarketplaceSan Francisco, CA, US · est. 2005

Prosper Marketplace: A San Francisco-based P2P lending service for loans, credit cards, and investments.

Series G · $490.5M468

Wells FargoSan Francisco, CA, USBanking, Wealth Managementest. 1852Wells FargoSan Francisco, CA, US · est. 1852

Wells Fargo provides banking, credit, payments, mortgage and wealth management services.